Page 40 - GTM-2-4

Global Translational Medicine The research advances in HPV integration

References [122] https://sqzbiotech.com/ patients-2/ https://sqzbiotech.com/ patients-2/ [123,124] [125,126] [127,128] (Cont’d...)

Status Phase I completed Phase I recruiting Phase I/II recruiting Phase I completed Phase I/II recruiting Phase II recruiting

None of the 5 patients immunized displayed a complete or partial In preclinical studies, SQZ ® AACs have been shown to induce robust immune responses to CD8 T-cell infiltration and were correlated In preclinical studies, SQZ ® eAPCs have been shown to generate robust CD8 + T cell responses to multiple antigens through simultaneous expression of the antigens CD86, membrane-bound IL-2 and Three patients (of 17 patients evaluated) displ

Treatment effect response with tumor reduction membrane-bound IL-12 density following clinical trials

Two novel Trojan peptide complexes, composed of MAGE-A3 and HPV 16 SQZ ® Activating Antigen Carriers (AACs), derived from engineered red blood cells, are designed to transport tumor-specific antigens and adjuvants to a patient’s own professional antigen-presenting cells. SQZ-AAC-HPV targets E6 and E7 oncoproteins Delivering five different mRNAs (targeting E6 and E7) to the patient’s SQZ-PBMC-HPV is a novel cancer vacci

Principle epitopes monocytes

MAGE-A3/HPV 16 Trojan peptides 0001 and 0002 SQZ-PBMC-HPV TG4001 and avelumab

Name SQZ-AAC-HPV SQZ-eAPC-HPV PDS0101 and pembrolizumab

MAGE-A3 positive tumor and/or HPV 16 positive head and neck squamous HPV16+metastatic solid HPV16+metastatic solid HPV16+metastatic solid Metastatic or refractory/ recurrent HPV16+cancer: cervical, vulvar, vaginal, papillomavirus-associated

Cancer type cell carcinoma tumors tumors tumors penile and anal High-risk human oropharynx cancer
Table 2. (Continued) Clinical trial No. NCT00257738 NCT04892043 NCT05357898 NCT04084951 NCT03260023 NCT05232851 NCT04260126

Volume 2 Issue 4 (2023) 14 https://doi.org/10.36922/gtm.2034